LDHB and breast carcinoma: MATN2 and SCGB2A2 are upregulated in ovarian cancer [20, 21]; S100P is upregulated in prostate cancer, invasive ductal carcinomas, and pancreatic cancer [22]; LDHB is a biomarker for triple negative breast cancer [23]; and TNC is associated with Tamoxifen resistance in breast cancer [24].